Latest news with #MED
Yahoo
7 days ago
- Business
- Yahoo
1 Safe-and-Steady Stock on Our Watchlist and 2 to Question
Low-volatility stocks may offer stability, but that often comes at the cost of slower growth and the upside potential of more dynamic companies. Luckily for you, StockStory helps you navigate which companies are truly worth holding. Keeping that in mind, here is one low-volatility stock that could succeed under all market conditions and two that may not deliver the returns you need. Rolling One-Year Beta: 0.22 Known for its Optavia program that combines portion-controlled meal replacements with coaching, Medifast (NYSE:MED) has a broad product portfolio of bars, snacks, drinks, and desserts for those looking to lose weight or consume healthier foods. Why Should You Dump MED? Products aren't resonating with the market as its revenue declined by 30.3% annually over the last three years Operating margin declined by 10.2 percentage points over the last year as its sales cratered Earnings per share have contracted by 27% annually over the last three years, a headwind for returns as stock prices often echo long-term EPS performance Medifast's stock price of $13.16 implies a valuation ratio of 0.4x forward price-to-sales. Dive into our free research report to see why there are better opportunities than MED. Rolling One-Year Beta: 0.77 Pioneering carbon-neutral flooring since its founding in 1973, Interface (NASDAQ:TILE) is a global manufacturer of modular carpet tiles, luxury vinyl tile (LVT), and rubber flooring that specializes in carbon-neutral and sustainable flooring solutions. Why Are We Out on TILE? Sales stagnated over the last five years and signal the need for new growth strategies Performance over the past five years shows each sale was less profitable, as its earnings per share fell by 3.5% annually Below-average returns on capital indicate management struggled to find compelling investment opportunities At $20.97 per share, Interface trades at 7.6x forward EV-to-EBITDA. If you're considering TILE for your portfolio, see our FREE research report to learn more. Rolling One-Year Beta: 0.74 Often located in suburban or semi-rural shopping centers, Ollie's Bargain Outlet (NASDAQ:OLLI) is a discount retailer that acquires excess inventory then sells at meaningful discounts. Why Is OLLI on Our Radar? Aggressive strategy of rolling out new stores to gobble up whitespace is prudent given its same-store sales growth Same-store sales growth averaged 4.1% over the past two years, showing it's bringing new and repeat shoppers into its stores Market share is on track to rise over the next 12 months as its 14.1% projected revenue growth implies demand will accelerate from its six-year trend Ollie's is trading at $112.16 per share, or 29.7x forward P/E. Is now the right time to buy? See for yourself in our comprehensive research report, it's free. Donald Trump's victory in the 2024 U.S. Presidential Election sent major indices to all-time highs, but stocks have retraced as investors debate the health of the economy and the potential impact of tariffs. While this leaves much uncertainty around 2025, a few companies are poised for long-term gains regardless of the political or macroeconomic climate, like our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today for free. Find your next big winner with StockStory today. Find your next big winner with StockStory today. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Washington Post
28-04-2025
- Business
- Washington Post
Medifast: Q1 Earnings Snapshot
BALTIMORE — BALTIMORE — Medifast Inc. (MED) on Monday reported a loss of $772,000 in its first quarter. On a per-share basis, the Baltimore-based company said it had a loss of 7 cents. Losses, adjusted for investment gains, were 11 cents per share. The weight-loss company posted revenue of $115.7 million in the period. For the current quarter ending in June, Medifast said it expects revenue in the range of $85 million to $105 million. _____ This story was generated by Automated Insights ( using data from Zacks Investment Research. Access a Zacks stock report on MED at
BBC News
28-04-2025
- Sport
- BBC News
Paralympian David Wetherill breaks marathon record on crutches
A former Team GB Paralympian has broken the record for running a marathon on crutches in the fastest Wetherill, who played table tennis at three Paralympic Games, has used crutches every day since he was 10 due to having a bone condition called multiple epiphyseal dysplasia (MED).Mr Wetherill, who lives in Plymouth but grew up in Torpoint, in Cornwall, completed the London Marathon on Sunday in 5:59:05, beating the previous record of 6:11:11. He said beating the record, combined with raising money for charity, made it "one of the most beautiful days of my life". 'A bit dazed' "It was unbelievable, honestly, probably the best achievement I've ever done", he told John Acres at Breakfast on BBC Radio Devon."That sense of achievement is unparalleled it was incredible."Mr Wetherill said the aim of completing the race in under six hours was motivating him towards the end of the marathon. "When I crossed the line I was a bit dazed," he said. "To beat it by 12 minutes in the end, obviously in the back of my mind that was driving me forward."The reason why we were doing this though was driving me much, much more."He added: "Yesterday was one of the most beautiful days of my life, if not the most beautiful." Mr Wetherill ran the marathon to raise money for type 1 diabetes charity Breakthrough T1D."I have unbelievable gratitude and thanks to everyone who has supported us," he said."We have raised about £15,000 and that's what it's all about really and that has just blown us away."The time and getting to the finish line is just beyond what we could have ever dreamt."
Yahoo
08-04-2025
- Business
- Yahoo
3 Reasons MED is Risky and 1 Stock to Buy Instead
What a brutal six months it's been for Medifast. The stock has dropped 29.3% and now trades at $13.05, rattling many shareholders. This was partly driven by its softer quarterly results and may have investors wondering how to approach the situation. Is now the time to buy Medifast, or should you be careful about including it in your portfolio? Dive into our full research report to see our analyst team's opinion, it's free. Even with the cheaper entry price, we don't have much confidence in Medifast. Here are three reasons why you should be careful with MED and a stock we'd rather own. Known for its Optavia program that combines portion-controlled meal replacements with coaching, Medifast (NYSE:MED) has a broad product portfolio of bars, snacks, drinks, and desserts for those looking to lose weight or consume healthier foods. Examining a company's long-term performance can provide clues about its quality. Any business can have short-term success, but a top-tier one grows for years. Over the last three years, Medifast's demand was weak and its revenue declined by 26.6% per year. This was below our standards and signals it's a low quality business. We track the change in earnings per share (EPS) because it highlights whether a company's growth is profitable. Sadly for Medifast, its EPS declined by 76.5% annually over the last three years, more than its revenue. This tells us the company struggled because its fixed cost base made it difficult to adjust to shrinking demand. If you've followed StockStory for a while, you know we emphasize free cash flow. Why, you ask? We believe that in the end, cash is king, and you can't use accounting profits to pay the bills. As you can see below, Medifast's margin dropped by 10.3 percentage points over the last year. Continued declines could signal it is in the middle of an investment cycle. Medifast's free cash flow margin for the trailing 12 months was 2.8%. We see the value of companies helping consumers, but in the case of Medifast, we're out. After the recent drawdown, the stock trades at 44× forward price-to-earnings (or $13.05 per share). At this valuation, there's a lot of good news priced in - we think there are better stocks to buy right now. We'd recommend looking at our favorite semiconductor picks and shovels play. The market surged in 2024 and reached record highs after Donald Trump's presidential victory in November, but questions about new economic policies are adding much uncertainty for 2025. While the crowd speculates what might happen next, we're homing in on the companies that can succeed regardless of the political or macroeconomic environment. Put yourself in the driver's seat and build a durable portfolio by checking out our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 175% over the last five years. Stocks that made our list in 2019 include now familiar names such as Nvidia (+2,183% between December 2019 and December 2024) as well as under-the-radar businesses like Sterling Infrastructure (+1,096% five-year return). Find your next big winner with StockStory today for free. Sign in to access your portfolio
BBC News
04-04-2025
- Sport
- BBC News
Devon Paralympian aiming for world marathon record on crutches
A former Team GB Paralympian says he wants to "show people what's possible" when he attempts to run the fastest marathon on Wetherill, who played table tennis at three Paralympic Games, was born with a bone condition called multiple epiphyseal dysplasia (MED) - meaning he has had to use crutches every day since he was 35-year-old entered the London Marathon on 27 April and wants to break the world record for the fastest marathon while using current record stands at 6:11:11 when it was set by East Sussex's Chris Terrill. Wetherill, who lives in Plymouth but grew up in Torpoint, said setting a new record would be great, but he also wanted to inspire others."It's never really about breaking records, it's what those actually mean and the wider purpose behind them," he said."If we can use this as a conduit to show people what's possible and raise some money, then that is the dream essentially." He ran his first marathon in Barcelona last year, registering an unofficial time of 5 hours and 44 minutes, which would have broken the existing said completing a marathon on crutches with his condition meant he had to battle through what he described as a "pain cave"."My hip is actually dangling out of its joint at the moment and I'm in pain whether I'm lying in bed or running marathons so my philosophy is I may as well run a marathon," he said. 'Pushing myself' Wetherill said living as an elite athlete and training like an "absolute animal" had improved his mental resilience over the years and he felt prepared to take on any challenge."I've been in situations in my life where I've felt quite helpless and I've felt in despair - I've felt like I can't do things," he said."Growing up with a disability, inherently you have those times, and it's not always easy, and I think that's why I'm so addicted to now pushing myself."I've not just got off the sofa and decided to run a marathon, I've almost been training for this my whole life."The London Marathon is on 27 April.
